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Abstract 
 
Systemic sclerosis (SSc) is a systemic autoimmune disease that is characterized by 
microangiopathy with progressive loss of capillaries and tissue fibrosis. Imatinib exerts potent 
anti-fibrotic effects and is currently evaluated in clinical trials. The aim of the present study 
was to exclude that the anti-fibrotic effects of imatinib are complicated by inhibitory effects 
on endothelial cell functions, which might augment vascular disease in SSc. 
Endothelial cells and mice were treated with pharmacologically relevant concentrations of 
imatinib. The expression of markers of vascular activation was assessed with real-time PCR. 
Proliferation was analyzed with the cell counting experiments and the MTT assay. Apoptosis 
was quantified with caspase 3 assays, annexin V in vitro and with TUNEL staining in vivo. 
Migration was studied with scratch and transwell assays. Tube forming was investigated with 
the matrigel assay.  
Imatinib did not alter the expression of markers of vascular activation. Imatinib did not 
increase the percentage of annexin V positive cells or the activity of caspase 3. No reduction 
in proliferation or metabolic activity of endothelial cells was observed. Imatinib did not affect 
migration of endothelial cells and did not reduce the formation of capillary tubes. Consistent 
with the in vitro data, no difference in the number of apoptotic endothelial cells was observed 
in vivo in mice treated with imatinib.  
Imatinib does not inhibit activation, viability, proliferation, migration or tube forming of 
endothelial cells in vitro and in vivo. Thus, treatment with imatinib might not augment further 
endothelial cell damage in SSc. 
 
Key words: imatinib, scleroderma, sclerosis, endothelial cells, angiogenesis, vasculopathy, 
fibrosis, c-abl, PDGF, TGFβ 
Main topics: novel anti-fibrotic therapies, microvascular disease in SSc
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Introduction 
 Systemic sclerosis (SSc) is an autoimmune disease of unknown aetiology that affects 
the skin and various internal organs. The most obvious histological feature of SSc is a 
massive accumulation of extracellular matrix components such as collagens, 
glycosaminoglycans and fibronectin [1]. The resulting fibrosis leads frequently to dysfunction 
of the affected organs. Tissue fibrosis contributes significantly to the high morbidity and the 
increased mortality of SSc.  
 We and others demonstrated recently that imatinib mesylate (Gleevec®/Glivec®) 
exerts potent anti-fibrotic effects [2,3]. Imatinib is a small molecule inhibitor that binds to the 
ATP-binding pocket of abelson kinase (c-abl) and blocks efficiently its tyrosine kinase 
activity. C-abl is an important downstream signalling molecule of TGFβ that mediates the 
pro-fibrotic effects of TGFβ independent of Smad 3/4 [2]. In addition to its effects on c-abl, 
imatinib mesylate blocks the tyrosine kinase activity of PDGF receptors [4]. Imatinib is 
widely used for the treatment of bcr-abl positive chronic myelogenous leukaemia and 
gastrointestinal stromal tumours. Clinical trials as well as post-marketing registries suggested 
that imatinib mesylate is well tolerated by these patients [4]. Due to the potent anti-fibrotic 
effects in several animal models, its favourable pharmacokinetics, the good clinical 
experience in other diseases and first promising case reports [5], clinical trials investigating 
the anti-fibrotic potential of imatinib in SSc are currently under way. 
 Besides fibrosis, a progressive microangiopathy is a characteristic feature of SSc. 
Increased apoptosis of microvascular endothelial cells as one of the first manifestations of 
vasculopathy occurs before tissue fibrosis becomes evident [1]. The ongoing endothelial cell 
damage results in a progressive loss of capillaries with decreased capillary blood flow, lack of 
nutrients and severe tissue hypoxia. The microangiopathy often manifests clinically as finger 
tip ulcers or even gangrene, and strongly contributes to the morbidity of SSc patients.  
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 Many novel drugs with potent anti-fibrotic activity in preclinical models such as Src 
kinase inhibitors might interfere with endothelial cell function [6,7]. Anti-angiogenic side 
effects might complicate the use of novel anti-fibrotic drugs in SSc patients as they might 
worsen the vascular manifestations of SSc. The aim of the present study was to determine, 
whether imatinib mesylate interferes with endothelial cell function and might thereby 
aggravate the vascular disease in SSc. 
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Material and Methods 
 
Cell culture 
Immortalized human microvascular endothelial (HMEC-1) cells were cultured as 
described previously [8].  
 
Incubation with imatinib mesylate 
HMEC-1 cells were incubated with imatinib mesylate in concentrations from 0.001 to 
1.0 µg/ml for 24 to 96 h. These concentrations correspond to the mean plasma peak and 
trough concentrations in humans after administration of standard doses of imatinib [2,3].  
 
Caspase 3 activity assay 
The activities of caspase-3-like proteases were determined using the EnzChek caspase-
3 assay kit (Invitrogen, Karlsruhe, Germany) as described [9].  
 
Quantification of apoptotic cells by staining for annexin V  
HMEC-1 cells were stained with fluorescein isothiocyanate-labeled annexin V (BD 
Bioscience, Heidelberg, Germany). Staining with annexin V in the absence of calcium was 
used for control. The number of cells positive for annexin V was quantified with the FACS 
Calibur flow cytometer.  
 
Microtiter tetrazolium (MTT) assay 
The metabolic activity of HMEC-1 cells incubated with imatinib for 24 to 96 h was 
assessed using the MTT [3, (4,5-dimethylthiazol-2-yl) 2,5-diphenyl-tetrazolium bromide] 
method. Fresh medium and imatinib mesylate were added every other day. Untreated HMEC 
were used as controls.  
 
 5
Quantitative real-time PCR 
Total RNA was isolated with the NucleoSpin RNA II extraction system (Machery-
Nagel, Düren, Germany) and reverse transcribed into complementary DNA (cDNA) with 
random hexamers. Gene expression was quantified by TaqMan or SYBR Green real-time 
PCR using the ABI Prism 7300 Sequence Detection System (Applied Biosystems, Forster 
City, CA, USA) as previously described [3]. Specific primer pairs for each gene are given in 
the supplementary text.  
 
Generation of proliferation curves 
HMEC-1 cells were seeded onto 6 well plates at a density of 1.3 x 104 cells/well and 
incubated with imatinib at concentrations from 0.1 to 1.0 µg/ml. Fresh medium and imatinib 
mesylate were added every other day. Untreated HMEC were used as controls. After 48, 72 
and 96 hours, cells were detached using trypsin and counted with a BD FACS Calibur flow 
cytometer. 
 
Scratch assay 
Confluent monolayers of HMEC-1 cells were wounded by scratching the surface 
uniformly with a pipette tip. The migration of cells into the scratched area was 
photographically monitored using the Spot Insight QE camera. Shortening of the distance 
between the two borders of the scratch was determined at three defined sites per sample after 
0, 24 and 48 hours.  
 
Chemotaxis assay 
The effect of imatinib on the chemotaxis of HMEC-1 cells was determined with a 
transwell chemotaxis assay using 24 well cell culture inserts with the bottom sealed by an 8 
µm pore polycarbonate-filter (Becton Dickinson, Heidelberg, Germany). The number of cells 
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that migrated through the filter to the lower compartment was quantified after 36 h with a 
FACS Calibur flow cytometer (Becton Dickinson). 
 
In vitro capillary morphogenesis assay 
To assess the influence of imatinib on the formation of tubes, an in vitro capillary 
morphogenesis assay was performed as described previously [10]. Tube forming was 
analyzed after 24 and 48 h. Representative images were obtained using an Axiovert 25 
microscope and a Spot Insight QE camera (Zeiss, Jena, Germany).  
 
Treatment of mice with bleomycin 
To investigate, whether treatment of fibrosis with imatinib induces apoptosis of 
endothelial cells under fibrotic conditions in vivo, dermal fibrosis was induced in female 6 
week-old C3H/HeJ mice (Sankyo, Tokyo, Japan) by local injection of bleomycin as described 
[3]. Two subgroups were additionally treated with imatinib mesylate in pharmacologically 
relevant doses of 50 mg/kg/d or 150 mg/kg/d.  
 
Terminal uridine deoxynucleotidyl transferase dUTP nick end labelling (TUNEL) assay  
Paraffin-embedded tissue sections from lesional skin of mice challenged with 
bleomycin were used to quantify the number of apoptotic endothelial cells. TUNEL staining 
was performed using the In situ cell death detection kit (Roche, Mannheim, Germany) as 
recommended by the manufacturer including positive and negative controls.  
 
Statistics 
Data are expressed as mean ± standard error of the mean. The Wilcoxon signed rank 
test for non-related samples were used for statistical analyses. A p-value of less than 0.05 was 
considered statistical significant. 
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Results 
Confirmation of the potent biologic effects of imatinib 
To demonstrate that imatinib exerts potent biological effects in the concentrations used 
in the study, dermal fibroblasts were incubated with imatinib in concentrations ranging from 
0.001 - 1.0 µg/ml. Imatinib potently decreased the levels of mRNA for col 1a1 and 
fibronectin-1. Similarly, significant anti-fibrotic effects with reduced accumulation of 
collagen were observed in mice treated with imatinib in doses of 50 mg/kg/d and 150 mg/kg/d 
(data not shown). Thus, imatinib exerts potent biologic effects in the concentrations used in 
the study.   
 
Effects of imatinib on the viability and proliferation of endothelial cells 
 The effect of imatinib on apoptosis of microvascular endothelial cells was analyzed by 
quantification of caspase 3 activity and staining for annexin V. After incubation with imatinib 
mesylate in concentrations from 0.001 - 1.0 µg/ml, no changes of the activity of caspase 3 
were detectable (Figure 1a). Incubation of HMEC-1 cells with increasing concentrations of 
imatinib did also not increase the number of annexin V positive, apoptotic cells (Figure 1b). 
To investigate, whether imatinib augments pre-existing endothelial cell damage, HMEC-1 
cells were serum starved and then incubated with imatinib. As under normal culture 
conditions, imatinib did neither induce activation of caspase 3 nor increase the number of 
apoptotic cells. 
Potential effects of imatinib mesylate on the metabolic activity and proliferation of 
endothelial cells were analyzed by MTT assay and by generating proliferation curves. No 
differences in metabolic activity were observed with the MTT assay between HMEC-1 cells 
treated with imatinib for 24 to 96 h and untreated controls (Figure 1c). Incubation with 
imatinib in pharmacologically relevant concentrations for up to 96 h also did not alter cell 
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counts (Figure 1d). Imatinib did also not increase the time period needed to reach 100 % 
confluence. 
 
Expression of markers for vascular activation by imatinib treated endothelial cells 
ICAM-1, VCAM-1, endothelin-1 and VEGF are differentially expressed in SSc and 
are common markers of endothelial cell activation. Incubation of HMEC-1 cells with imatinib 
did not change the expression of ICAM-1, VCAM-1, endothelin-1 and VEGF (data not 
shown), suggesting that imatinib might not alter the activation of endothelial cells.  
HMEC-1 cells expressed mRNA for PDGF recptor α (PDGFRα), PDGFRβ and c-kit, 
which are established targets of imatinib. Incubation with imatinib did not alter the expression 
of these genes in HMEC-1 cells (data not shown).  
 
Effects of imatinib on migration, chemotaxis and tube forming 
To assess, whether imatinib reduces the migration of endothelial cells, scratch assays 
were performed. No differences in the distance between the two borders of the scratch were 
observed in HMEC-1 cells incubated with imatinib compared to untreated controls after 24 h 
and 48 h (Figures 2a and b). The time until closure of the scratch was also not prolonged.  
To study the effects of imatinib on chemotaxis of endothelial cells, a micro-
chemotaxis assay was performed. Imatinib did not reduce the number of migrated HMEC-1 
cells (Figure 2c).    
Next, we analyzed, whether imatinib inhibits tube formation using an in vitro capillary 
morphogenesis assay. Imatinib did not reduce the number of tubes, the maximal length of the 
capillary tubes or the number of branching points (Figure 2f), suggesting that imatinib does 
not affect tube formation in vitro. 
 
Apoptosis of endothelial cells in mice treated with imatinib 
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To evaluate, whether imatinib induces apoptosis of endothelial cells in vivo under 
fibrotic conditions, the number of apoptotic endothelial cells in mice challenged with 
bleomycin were quantified by TUNEL staining. Treatment of mice with imatinib in doses of 
50 mg/kg/d for 4 weeks did not increase the number of TUNEL positive apoptotic endothelial 
cells compared to bleomycin alone (Figure 3). Similarly, no increase in apoptotic endothelial 
cells was detectable in mice treated with imatinib at 150 mg/kg/d.
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Discussion 
In the present study, we demonstrate that imatinib does not induce apoptosis or inhibit 
proliferation of microvascular endothelial cells in vitro and in vivo. Imatinib did also not 
affect activation of endothelial cells, reduce migration and chemotaxis or decrease the 
formation of capillary tubes. Together, these data suggest that imatinib does not affect major 
functions of endothelial cells. The lack of vascular side effects of imatinib observed herein is 
supported by first case reports describing the use of imatinib in patients with SSc and related 
fibrosing disorders [5,11,12]. All patients reported in these case series experienced a strong 
regression of fibrosis and tolerated imatinib well. No vascular side effects such as 
exacerbation of Raynaud´s phenomenon or increased frequency of fingertip ulcers were 
reported. Thus, treatment with imatinib might not be complicated by vascular side effects 
under physiological conditions. In contrast to the results obtained in our study, imatinib 
increased apoptosis, reduced migration and increased intercellular permeability in the EA.hy 
926 endothelial cell line [13]. However, the concentrations of imatinib used in this study were 
significantly higher than in our study and exceed by far the concentrations needed for 
antifibrotic effects and the peak concentrations in human plasma after standard doses.     
In SSc, ongoing damage of endothelial cells occurs via several distinct mechanisms. 
Cross reactivity with antibodies against cytomegalovirus, anti-endothelial cell autoantibodies 
and microparticles all have been implicated in the vascular pathogenesis of SSc [1]. Although 
we did not observe inhibitory effects of imatinib on major functions of endothelial cells, we 
cannot exclude that imatinib might inhibit functions of endothelial cells that have previously 
been affected by autoantibodies or microparticles. However, imatinib did not increase 
apoptosis of serum starved, pre-damaged HMEC-1 cells, indicating that imatinib does not 
enhance pre-existing damage of endothelial cells in general. Furthermore, first case reports of 
SSc patients treated with imatinib did not report exacerbations of vascular manifestations of 
SSc [5]. Another limitation of our study is that we worked with immortalized HMEC-1 cells. 
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Although the phenotype of these cells resembles closely that of primary microvascular 
endothelial cells [8], these cells might still be less sensitive to imatinib than primary cells.  
Although we did not observe toxic effects on endothelial cells in vitro and in our 
mouse model in vivo, we cannot exclude anti-angiogenic effects in other settings via 
inhibition of pericytes. PDGF signalling is crucial for several functions of pericytes and 
inhibition of the tyrosine kinase activity of PDGFR by imatinib reduced migration, 
proliferation and survival of pericytes [14-16]. Another concern might the potential risk of 
cardiotoxicity as a small number of patients developed cardiomyopathy while on imatinib 
[17,18]. 
In summary, we demonstrate that imatinib does not inhibit major functions of 
endothelial cells. Thus, based on preclinical models, the anti-fibrotic activity of imatinib does 
not seem to be accompanied by unwanted side effects on endothelial cells and imatinib might 
worsen the preexisting vascular damage in SSc.  
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Figure legends 
 
Figure 1: Imatinib does not induce apoptosis, reduce the metabolic activity or decrease 
proliferation of endothelial cells. Figures 1a and b: Incubation with imatinib in 
concentrations from 0.001 – 1.0 µg/ml for 24 h did not increase the activity of caspase 3 (n = 
3) (Figure 1a) or the number of annexin V positive HMEC-1 cells (n = 9) (Figure 1b). 
Figure 1c: Incubation with imatinib in pharmacologically relevant concentrations for 48 h did 
not reduce the metabolic activity of HMEC-1 cells compared to cells incubated with medium 
only (n = 5). In contrast, incubation with 50 % DMSO profoundly reduced the metabolic 
activity. Figure 1d: Imatinib did not reduce proliferation of HMEC-1 cells as analyzed by 
direct cell counting (n = 6). 
 
Figure 2: Imatinib does not affect migration, chemotaxis or tube formation of endothelial 
cells. Figures 2a and b: Imatinib does not reduce cell migration in the scratch assay. The 
distances between the borders of the scratch were not increased in imatinib treated HMEC-1 
cells at various time-points. Representative images taken after 48 h from untreated cells and 
HMEC-1 cells incubated with 0.1 µg/ml and 1.0 µg/ml imatinib are shown at 100 fold 
magnification in Figures 2a and summarized in Figure 2b (n = 6). Figure 2c: Imatinib does 
not inhibit chemotaxis of HMEC-1 cells in the transwell assay. The number of HMEC-1 cells 
that migrated through the 8 µm pores did not differ between HMEC-1 cells incubated with 
imatinib and controls (n = 8). Figure 2d: Imatinib does not inhibit the formation of capillary 
tubes. Imatinib did not reduce the number of tubes, the maximal length of the capillary tubes 
or the number of branching points. Representative images from controls and HMEC-1 cells 
treated with imatinib in concentrations of 0.1 µg/ml and 1.0 µg/ml are shown at 50 fold 
magnification (n = 15).  
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Figure 3: Imatinib does not induce apoptosis of endothelial cells in vivo. The number of 
apoptotic endothelial cells upon treatment with imatinib in vivo was quantified in the mouse 
model of bleomycin induced dermal fibrosis. Treatment with imatinib at doses of 50 mg/kg/d 
and 150 mg/kg/d did not increase the number of apoptotic endothelial cells (n = 6 for each 
group).  
 
 
 
 
 
 
 16
